DDInter1327 DDInter1658
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Voriconazole
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Voriconazole